[1] See E, Ronco C,Bellomo R. The future of continuous renal replacement therapy[J].Semin Dial,2021,34(6):576-585.
[2] Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study[J].Intensive Care Med,2015,41(8):1411-1423.
[3] Tandukar S,Palevsky PM. Continuous renal replacement therapy: Who, When, Why, and How[J].Chest,2019,155(3):626-638.
[4] Karkar A,Ronco C. Prescription of CRRT: a pathway to optimize therapy[J].Ann Intensive Care,2020,10(1):32.
[5] Kovvuru K,Velez JCQ. Complications associated with continuous renal replacement therapy[J].Semin Dial,2021,34(6):489-494.
[6] Tsujimoto Y, Miki S, Shimada H, et al. Non-pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy[J].Cochrane Database Syst Rev,2021,9(9):Cd013330.
[7] Zhang W, Bai M, Yu Y, et al. Continuous renal replacement therapy without anticoagulation in critically ill patients at high risk of bleeding: A systematic review and meta-analysis[J].Semin Dial,2021,34(3):196-208.
[8] Doi K, Nishida O, Shigematsu T, et al. The Japanese Clinical Practice Guideline for acute kidney injury 2016[J].J Intensive Care,2018,6:48.
[9] Maruyama Y, Yoshida H, Uchino S, et al. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study[J].Int J Artif Organs,2011,34(7):571-576.
[10] Lee YK, Lee HW, Choi KH, et al. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study[J].PLoS One,2014,9(10):e108737.
[11] 北村伸哉, 张凌. 甲磺酸萘莫司他在连续性肾脏替代治疗中的抗凝应用[J].华西医学,2018,33(07):801-805.
[12] Willers A, Arens J, Mariani S, et al. New trends, advantages and disadvantages in anticoagulation and coating methods used in extracorporeal life support devices[J].Membranes (Basel),2021,11(8):617.
[13] Hwang SD, Hyun YK, Moon SJ, et al. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy[J].Int J Artif Organs,2013,36(3):208-216.
[14] Arimura T, Abe M, Shiga H, et al. Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013[J].J Artif Organs,2017,20(3):244-251.
[15] 刘志艳, 向倩,崔一民. 甲磺酸萘莫司他临床应用的研究现状[J].中国临床药理学杂志,2020,36(15):2368-2372.
[16] Choi JY, Kang YJ, Jang HM, et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: A randomized clinical trial[J].Medicine (Baltimore),2015,94(52):e2392.
[17] Makino S, Egi M, Kita H, et al. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy[J].Int J Artif Organs,2016,39(1):16-21.
[18] Miyatake Y, Makino S, Kubota K, et al. Association between intra-circuit activated clotting time and incidence of bleeding complications during continuous renal replacement therapy using nafamostat mesilate: a retrospective pilot observational study[J].Kobe J Med Sci,2017,63(1):e30-e36.
[19] Lim JY, Kim JB, Choo SJ, et al. Anticoagulation during extracorporeal membrane oxygenation; nafamostat mesilate versus heparin[J].Ann Thorac Surg,2016,102(2):534-539.
[20] Park JH, Her C, Min HK, et al. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation[J].Int J Artif Organs,2015,38(11):595-599.
[21] Goto S, Ookawara S,Saito A. Differences in the adsorption of nafamostat mesilate between polyester-polymer alloy and polysulfone membranes[J].J Artif Organs,2017,20(2):138-144.
[22] Hirayama T, Nosaka N, Okawa Y, et al. AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study[J].J Intensive Care,2017,5:46.
[23] Nakamura Y, Hara S, Hatomoto H, et al. Adsorption of nafamostat mesilate on AN69ST membranes: a single-center retrospective and in vitro study[J].Ther Apher Dial,2017,21(6):620-627.
[24] Baek NN, Jang HR, Huh W, et al. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding[J].Ren Fail,2012,34(3):279-285.
[25] Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study[J].Jama,2005,294(7):813-818.
[26] Hanafusa N. Application of continuous renal replacement therapy: what should we consider based on existing evidence?[J].Blood Purif,2015,40(4):312-319.
[27] Miyaji MJ, Ide K, Takashima K, et al. Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy[J].Pediatr Nephrol,2022, 10.1007/s00467-022-05502-8.[Online ahead of print]
[28] Abrams D, Combes A,Brodie D. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults[J].J Am Coll Cardiol,2014,63(25 Pt A):2769-2778.
[29] Han SJ, Kim HS, Kim KI, et al. Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation[J].J Korean Med Sci,2011,26(7):945-950.
[30] Han W, San Bok J, Cho HJ, et al. Single-center experience of extracorporeal membrane oxygenation mainly anticoagulated with nafamostat mesilate[J].J Thorac Dis,2019,11(7):2861-2867.
[31] Han SJ, Han W, Song HJ, et al. Validation of nafamostat mesilate as an anticoagulant in extracorporeal membrane oxygenation: a large-animal experiment[J].Korean J Thorac Cardiovasc Surg,2018,51(2):114-121.
[32] Zhou Z, Kuang H, Ma Y, et al. Application of extracorporeal therapies in critically ill COVID-19 patients[J].J Zhejiang Univ Sci B,2021,22(9):701-717.
[33] Asakura H,Ogawa H. Potential of heparin and nafamostat combination therapy for COVID-19[J].J Thromb Haemost,2020,18(6):1521-1522.
[34] Doi S, Akashi YJ, Takita M, et al. Preventing thrombosis in a COVID-19 patient by combinatorial therapy with nafamostat and heparin during extracorporeal membrane oxygenation[J].Acute Med Surg,2020,7(1):e585.
[35] Kinugasa E, Akizawa T, Nakashima Y, et al. Nafamostat as anti-coagulant for membrane plasmapheresis in high bleeding risk patients[J].Int J Artif Organs,1992,15(10):595-600.
[36] Abe H, Tani T, Numa K, et al. Efficacy of nafamostat mesilate as a regional anticoagulant in experimental direct hemoperfusion and in plasma exchange on humans[J].Artif Organs,1992,16(2):206-208.
[37] Nakae H, Fukuda H, Okuyama M, et al. Selective plasma exchange for critically ill patients accompanied with thrombocytopenia[J].Ther Apher Dial,2016,20(4):339-341.
[38] Nakae H, Igarashi T,Tajimi K. The dose of nafamostat mesilate during plasma exchange with continuous hemodiafiltration in the series-parallel circuit[J].Ther Apher Dial,2006,10(3):233-236.
[39] Nakamura Y, Tada K, Matsuta M, et al. Anaphylactic reactions caused by nafamostat mesylate during hemodialysis before surgery for carpal tunnel syndrome[J].Case Rep Nephrol,2021,2021:1148156.
[40] Kim JH, Park JY, Jang SH, et al. Fatal anaphylaxis due to nafamostat mesylate during hemodialysis[J].Allergy Asthma Immunol Res,2021,13(3):517-519.
